The purpose of the study is to investigate the long-term safety and the antiviral activity of the optimal doses of LB80380 for additional 48 weeks in treatment-naive patients with chronic hepatitis B infection compared to entecavir 0.5 mg.

LB80380, an oral prodrug, is a promising candidate nucleotide analogue with antiviral activity against wild-type hepatitis B virus (HBV). LB80380 is undergoing clinical development by LG Life Sciences for use in the treatment of chronic HBV infection.

This study is an extension study of the Phase IIb (Protocol No. LG-BVCL007), the treatment period of this study is 48-week with 24-week of follow-up period

Inclusion Criteria:

• The patients who are able to participate in this expanded study without any interruption after completing 48 weeks treatment of LG-BVCL007 study

Exclusion Criteria:

• Co-infection with hepatitis C or D virus (HCV or HDV) or HIV
• Decompensated liver disease
• ALT > 10 x ULN
• Creatinine clearance (calculated by cockcroft-gault formula) less than 50 ml/min
• Alpha-fetoprotein (AFP) value greater than or equal to 50 ng/mL, and a follow-up ultrasonography performed prior to baseline shows findings indicative of HCC
• Treatment with immunomodulatory agent or corticosteroids within 6 months prior to study entry.
• Pregnancy or breast-feeding
• Patient is currently abusing alcohol or illicit drugs
• Significant systemic illnesses other than liver diseases
• Presence of other causes of liver disease
• Plan for liver transplantation